Harmony Biosciences Holdings (HRMY) Stock Forecast & Price Target

Compare

397 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HRMY Analyst Ratings

Strong Buy

9 Buy

0 Hold

1 Sell

Based on 10 analysts giving stock ratings to

Harmony

Biosciences Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HRMY Stock 12 Month Forecast

Average Price Target

$46.00

▲(29.36% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Harmony Biosciences Holdings in the last 3 months. The average price target is $46.00 with a high forecast of $62.00 and a low forecast of $32.00. The average price target represents a 29.36% change from the last price of $35.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","44":"$44","63":"$63","34.5":"$34.5","53.5":"$53.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,34.5,44,53.5,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.57,31.141538461538463,33.713076923076926,36.284615384615385,38.856153846153845,41.42769230769231,43.99923076923077,46.57076923076923,49.142307692307696,51.713846153846156,54.285384615384615,56.85692307692308,59.42846153846154,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.57,29.91076923076923,31.251538461538463,32.59230769230769,33.933076923076925,35.27384615384615,36.614615384615384,37.95538461538462,39.29615384615384,40.636923076923075,41.97769230769231,43.318461538461534,44.65923076923077,{"y":46,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.57,28.833846153846153,29.09769230769231,29.361538461538462,29.625384615384615,29.88923076923077,30.153076923076924,30.416923076923077,30.68076923076923,30.944615384615386,31.20846153846154,31.472307692307695,31.736153846153847,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$62.00

Average Price Target$46.00

Lowest Price Target$32.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$55

Buy

54.67%

Upside

Reiterated

11/24/25

Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth PotentialValuation and Risks. We assess Harmony using a risk-adjusted discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology on free cash flow to the firm (FCFF) and net income per asset, respectively. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. Although pitolisant-GR is expected to have a unique brand, we expect pricing to be similar to pitolisant-IR.

Ami Fadia

Needham

$42

Buy

18.11%

Upside

Reiterated

11/24/25

Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences

Graig Suvannavejh

Mizuho Securities

―

Buy

―

Reiterated

11/13/25

Harmony Biosciences Holdings (HRMY) Receives a Buy from Mizuho Securities

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

11/05/25

Truist Financial Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)

Jason Gerberry

Bank of America Securities

$31→$32

Sell

-10.01%

Downside

Reiterated

11/04/25

Harmony Biosciences price target raised to $32 from $31 at BofAHarmony Biosciences price target raised to $32 from $31 at BofA

Ashwani Verma

UBS

$50→$43

Buy

20.92%

Upside

Reiterated

10/14/25

UBS Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)

David Amsellem

Piper Sandler

$48

Buy

34.98%

Upside

Reiterated

09/25/25

Piper Sandler Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)

David Hoang

Deutsche Bank

$54→$36

Buy

1.24%

Upside

Reiterated

09/25/25

Harmony Biosciences price target lowered to $36 from $54 at Deutsche BankHarmony Biosciences price target lowered to $36 from $54 at Deutsche Bank

Charles Duncan

Cantor Fitzgerald

$54→$50

Buy

40.61%

Upside

Reiterated

09/24/25

Harmony Biosciences Holdings (HRMY) Receives a Buy from Cantor Fitzgerald

Andreas Argyrides

Oppenheimer

$70→$62

Buy

74.35%

Upside

Reiterated

09/24/25

Oppenheimer Remains a Buy on Harmony Biosciences Holdings (HRMY)

Corinne Johnson

Goldman Sachs

$33

Hold

-7.20%

Downside

Initiated

07/10/25

Harmony Biosciences Holdings (HRMY) Gets a Hold from Goldman Sachs

Francois Brisebois

LifeSci Capital

$61

Buy

71.54%

Upside

Reiterated

04/08/25

Oppenheimer on Harmony Biosciences (HRMY): we remain pleased with WAKIXs 4Q24 performanceOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $61.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$55

Buy

54.67%

Upside

Reiterated

11/24/25

Ami Fadia

Needham

$42

Buy

18.11%

Upside

Reiterated

11/24/25

Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences

Graig Suvannavejh

Mizuho Securities

―

Buy

―

Reiterated

11/13/25

Harmony Biosciences Holdings (HRMY) Receives a Buy from Mizuho Securities

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

11/05/25

Truist Financial Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)

Jason Gerberry

Bank of America Securities

$31→$32

Sell

-10.01%

Downside

Reiterated

11/04/25

Harmony Biosciences price target raised to $32 from $31 at BofAHarmony Biosciences price target raised to $32 from $31 at BofA

Ashwani Verma

UBS

$50→$43

Buy

20.92%

Upside

Reiterated

10/14/25

UBS Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)

David Amsellem

Piper Sandler

$48

Buy

34.98%

Upside

Reiterated

09/25/25

Piper Sandler Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)

David Hoang

Deutsche Bank

$54→$36

Buy

1.24%

Upside

Reiterated

09/25/25

Harmony Biosciences price target lowered to $36 from $54 at Deutsche BankHarmony Biosciences price target lowered to $36 from $54 at Deutsche Bank

Charles Duncan

Cantor Fitzgerald

$54→$50

Buy

40.61%

Upside

Reiterated

09/24/25

Harmony Biosciences Holdings (HRMY) Receives a Buy from Cantor Fitzgerald

Andreas Argyrides

Oppenheimer

$70→$62

Buy

74.35%

Upside

Reiterated

09/24/25

Oppenheimer Remains a Buy on Harmony Biosciences Holdings (HRMY)

Corinne Johnson

Goldman Sachs

$33

Hold

-7.20%

Downside

Initiated

07/10/25

Harmony Biosciences Holdings (HRMY) Gets a Hold from Goldman Sachs

Francois Brisebois

LifeSci Capital

$61

Buy

71.54%

Upside

Reiterated

04/08/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Harmony Biosciences Holdings

1 Month

xxx

Success Rate

9/14 ratings generated profit

Average Return

+6.17%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +6.17% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+6.14%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +6.14% per trade.

1 Year

Francois BriseboisLifeSci Capital

Success Rate

7/14 ratings generated profit

Average Return

+2.64%

reiterated a buy rating 8 months ago

Copying Francois Brisebois's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.64% per trade.

2 Years

xxx

Success Rate

6/15 ratings generated profit

Average Return

-4.64%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -4.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HRMY Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HRMY has received 30 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. HRMY average Analyst price target in the past 3 months is 46.00.

Each month's total comprises the sum of three months' worth of ratings.

HRMY Financial Forecast

HRMY Earnings Forecast

Next quarter’s earnings estimate for HRMY is $0.85 with a range of $0.60 to $1.21. The previous quarter’s EPS was $0.87. HRMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year HRMY has Performed in-line its overall industry.

HRMY Sales Forecast

Next quarter’s sales forecast for HRMY is $237.98M with a range of $231.67M to $242.35M. The previous quarter’s sales results were $239.46M. HRMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year HRMY has Performed in-line its overall industry.

HRMY Stock Forecast FAQ

What is HRMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Harmony Biosciences Holdings’s 12-month average price target is 46.00.

What is HRMY’s upside potential, based on the analysts’ average price target?

Harmony Biosciences Holdings has 29.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HRMY a Buy, Sell or Hold?

Harmony Biosciences Holdings has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 1 sell ratings.

What is Harmony Biosciences Holdings’s price target?

The average price target for Harmony Biosciences Holdings is 46.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.00 ,the lowest forecast is $32.00. The average price target represents 29.36% Increase from the current price of $35.56.

What do analysts say about Harmony Biosciences Holdings?

Harmony Biosciences Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of HRMY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Harmony Biosciences Holdings (HRMY) Stock Forecast & Price Target

HRMY Analyst Ratings

HRMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Harmony Biosciences Holdings

HRMY Analyst Recommendation Trends

HRMY Financial Forecast

HRMY Earnings Forecast

HRMY Sales Forecast

HRMY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts